key: cord-0925222-jeos1cqr
authors: Torres, Ignacio; Qualai, Jamal; Albert, Eliseo; Bueno, Felipe; Huntley, Dixie; Poujois, Sandrine; Gil, María Teresa; Navarro, David
title: Real‐life evaluation of a rapid extraction‐free SARS‐CoV‐2 RT‐PCR assay (COVID‐19 PCR Fast‐L) for the diagnosis of COVID‐19
date: 2021-05-03
journal: J Med Virol
DOI: 10.1002/jmv.27039
sha: 43f7ed041e3b214a3ef654d9fd6df16820a19c02
doc_id: 925222
cord_uid: jeos1cqr

nan

Real-life evaluation of a rapid extraction-free SARS-CoV-2 RT-PCR assay (COVID-19 PCR Fast-L) for the diagnosis of COVID-19

To the Editor, Timely and rapid diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by reverse transcriptionpolymerase chain reaction (RT-PCR) is paramount to the control of the coronavirus disease 2019 (COVID-19) pandemic. Attempts have been made to shorten molecular testing turnaround by skipping nucleic acid extraction, thus performing RT-PCR directly on heattreated respiratory specimens. A number of either "in-house"developed or commercial (i.e., Cepheid Xpert Xpress SARS-CoV-2 assay) RT-PCR or loop-mediated amplification protocols have been developed and found to display clinical sensitivities ranging from 75% to 98% when compared to RT-PCR preceded by viral RNA extraction. [1] [2] [3] [4] [5] [6] [7] [8] [9] Here, we conducted a real-life evaluation of the performance of a commercially-available free-extraction RT-PCR, the Ascires COVID-19 PCR Fast-L (Sistemas Genómicos®), which is multiplexed to amplify two conserved sequences within ORF-1ab/1a (FAM and CY5 channels), one of which lies within the RdRP gene (FAM channel) and returns qualitative results in less than 1 h. In this assay, nasopharyngeal (NP) specimens are transferred to 1 ml of transport/extraction buffer containing proteinase K provided by the manufacturer, placed in a dry bath at 60°C for 5 min, then at 98°C for 2 min, and finally on ice for cooling. Target amplification is carried out using the AriaMx Real-Time PCR System (Agilent®), and results are analyzed and interpreted automatically by The AriaMx Software version 1.5. Thermal cycling conditions are shown in the footnote of Table 1 . The assay includes an internal heterologous DNA control (HEX probe). According to the manufacturer, the limit of detection range: 23-31, corresponding to a median of 5.44 log 10 copies/ml; range: 3.98-6.51). Accordingly, a direct relationship was found between PPA and SARS-CoV-2 RNA load in NP (Table 1 ). In fact, PPA was maximum (100%) with SARS CoV-2 RNA with loads ≥6.8 log 10 SARS CoV-2 RNA copies/ml, which roughly corresponds to the viral load threshold above which viable SARS-CoV-2 virus could be recovered from cell culture. 10 In summary, the free-extraction COVID-19 PCR Fast-L assay, although less sensitive than the comparator RT-PCR used herein, is a reliable test for diagnosis of SARS-CoV-2 infection when NP specimens harbor relatively high viral loads. 

The authors declare that there are no conflict of interests. The AMPLIRUN® TOTAL SARS-CoV-2 RNA Control (Vircell S.A) was used as the reference material for SARS-CoV-2 RNA load quantitation.

Improved COVID-19 testing by extraction-free SARS-CoV-2 RT-PCR

Extraction-free protocol combining proteinase K and heat inactivation for detection of SARS-CoV-2 by RT-qPCR

Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary respiratory materials

Direct-RT-qPCR detection of SARS-CoV-2 without RNA extraction as part of a COVID-19 testing strategy: from sample to result in one hour

A simple method for SARS-CoV-2 detection by rRT-PCR without the use of a commercial RNA extraction kit

Evaluating the efficacy of RT-qPCR SARS-CoV-2 direct approaches in comparison to RNA extraction

COVID-19 diagnostics for resource-limited settings: evaluation of "unextracted" qRT-PCR

Laboratory management for SARS-CoV-2 detection: a user-friendly combination of the heat treatment approach and rt-Real-time PCR testing

Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR

Field evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres